Generate Biomedicines, Inc. (GENB) Balance Sheet
GENB balance sheet, 2025
December 31, 2025 · U.S. dollars$330.2M assets = $953.4M liabilities + −$623.2M equity
Liabilities exceed assets: shareholders’ equity is negative (−$623.2M).
Both columns are drawn to the same scale: what GENB owns equals what it owes plus shareholders’ equity. Hover a block for its value.
GENB financial health
Descriptive bands, not a rating. Fiscal 2025.
GENB balance sheet trends, 2024–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $518.3M2024 | $330.2M2025 | −36.3%/yr | |
| Total liabilities | $953.3M2024 | $953.4M2025 | +0.0%/yr | |
| Shareholders’ equity | −$434.5M2024 | −$616.0M2025 | — | |
| Cash & short-term investments | $393.6M2024 | $221.5M2025 | −43.7%/yr | |
| Total debt | $77.0M2024 | $68.5M2025 | −11.0%/yr | |
| Net cash (debt) | $316.7M2024 | $153.0M2025 | −$163.7M | |
| Working capital | $320.9M2024 | $152.2M2025 | −$168.7M | |
| Book value per share | −$3.412024 | −$12.302025 | — | |
| Current ratio | 4.702024 | 2.852025 | −1.85 | |
| Shares outstanding | 127.5M2024 | 50.1M2025 | −60.7%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
GENB assets
GENB liabilities and equity
GENB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
GENB balance sheet
| 2025 | 2024 | |
|---|---|---|
| Assets | ||
| Cash & short-term investments | $221.5M | $393.6M |
| Cash & equivalents | $121.7M | $176.3M |
| Short-term investments | $99.8M | $217.4M |
| Receivables | $0 | $308,000 |
| Inventory | $0 | $0 |
| Other current assets | $12.9M | $13.6M |
| Total current assets | $234.4M | $407.5M |
| Property, plant & equipment (net) | $89.0M | $101.1M |
| Goodwill & intangible assets | $0 | $0 |
| Long-term investments | $0 | $0 |
| Other non-current assets | $6.8M | $9.7M |
| Total assets | $330.2M | $518.3M |
| Liabilities | ||
| Accounts payable | $3.8M | $5.7M |
| Short-term debt | $15.0M | $16.7M |
| Deferred revenue | $21.2M | $42.4M |
| Total current liabilities | $82.2M | $86.6M |
| Long-term debt | $0 | $0 |
| Lease obligations | $68.5M | $77.0M |
| Other long-term liabilities | $871.2M | $866.7M |
| Total liabilities | $953.4M | $953.3M |
| Shareholders' equity | ||
| Common stock & paid-in capital | $50,000 | $50,000 |
| Retained earnings (deficit) | −$676.3M | −$473.1M |
| Accumulated other comprehensive income | $106,000 | $118,000 |
| Minority interest | −$7.2M | −$571,000 |
| Total shareholders' equity | −$616.0M | −$434.5M |
| Key figures | ||
| Total debt | $68.5M | $77.0M |
| Net cash (debt) | $153.0M | $316.7M |
| Working capital | $152.2M | $320.9M |
| Tangible book value | −$616.0M | −$434.5M |
| Book value per share | −$12.30 | −$3.41 |
| Shares outstanding | 50.1M | 127.5M |
| Current ratio | 2.85 | 4.70 |
| Quick ratio | 2.69 | 4.55 |
| Equity / assets | −186.6% | −83.8% |
| Jun '26 | Mar '26 | |
|---|---|---|
| Assets | ||
| Cash & short-term investments | $457.4M | $516.6M |
| Cash & equivalents | $135.4M | $160.6M |
| Short-term investments | $322.1M | $356.1M |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other current assets | $12.8M | $18.7M |
| Total current assets | $470.3M | $535.4M |
| Property, plant & equipment (net) | $82.4M | $85.6M |
| Goodwill & intangible assets | $0 | $0 |
| Long-term investments | $0 | $0 |
| Other non-current assets | $9.1M | $4.7M |
| Total assets | $561.7M | $625.7M |
| Liabilities | ||
| Accounts payable | $5.7M | $7.6M |
| Short-term debt | $13.6M | $14.3M |
| Deferred revenue | $12.2M | $17.2M |
| Total current liabilities | $56.6M | $58.4M |
| Long-term debt | $0 | $0 |
| Lease obligations | $62.6M | $65.6M |
| Other long-term liabilities | $49.0M | $52.5M |
| Total liabilities | $105.6M | $110.9M |
| Shareholders' equity | ||
| Common stock & paid-in capital | $128,000 | $128,000 |
| Retained earnings (deficit) | −$805.0M | −$737.7M |
| Accumulated other comprehensive income | −$129,000 | $24,000 |
| Minority interest | $0 | $0 |
| Total shareholders' equity | $456.0M | $514.8M |
| Key figures | ||
| Total debt | $62.6M | $65.6M |
| Net cash (debt) | $394.8M | $451.1M |
| Working capital | $413.6M | $477.0M |
| Tangible book value | $456.0M | $514.8M |
| Book value per share | $3.56 | $4.02 |
| Shares outstanding | 128.2M | 128.2M |
| Current ratio | 8.30 | 9.17 |
| Quick ratio | 8.08 | 8.85 |
| Debt / equity | 0.14 | 0.13 |
| Equity / assets | 81.2% | 82.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed December 31, 2025); data from EODHD.
GENB financial position
At the end of fiscal 2025 (December 31, 2025), Generate Biomedicines had total assets of $330.2 million (down 36.3% from a year earlier), total liabilities of $953.4 million and shareholders' equity of -$616.0 million. It held $221.5 million in cash and short-term investments against $68.5 million of debt, a net cash position of $153.0 million. Its current ratio was 2.85. In the latest quarter (ended June 30, 2026) total assets were $561.7 million and equity $456.0 million.
Related: GENB income statement, GENB cash flow statement, GENB key metrics. See the GENB stock overview for the latest quote and news.
GENB balance sheet FAQ
What are Generate Biomedicines's total assets?
Generate Biomedicines reported total assets of $330.2 million at the end of fiscal 2025 (December 31, 2025), compared with $518.3 million a year earlier.
How much debt does Generate Biomedicines have?
Generate Biomedicines had $68.5 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was —.
How much cash does Generate Biomedicines have?
Generate Biomedicines held $221.5 million in cash and short-term investments at the end of fiscal 2025; with $68.5 million of debt that is net cash of $153.0 million.
What is Generate Biomedicines's book value?
Generate Biomedicines's shareholders' equity (book value) was -$616.0 million at the end of fiscal 2025, or −$12.30 per share.
What is Generate Biomedicines's current ratio?
Generate Biomedicines had current assets of $234.4 million and current liabilities of $82.2 million, a current ratio of 2.85 (it can cover its short-term obligations).